MedicalNews

Biogelx and Regemat 3D partner to provide complete 3D bioprinting solutions

Scottish biomaterial developer, Biogelx, and Regemat 3D, a Spain manufacturer of bioprinting systems, have partnered to develop a new skin model as well as offering complete bioprinting solutions for research institutes worldwide.

“We are excited to see future tissue models using Biogelx-INKs,” said Sandy Bulloch, Director of Strategic Alliances, Biogelx.

“We believe that this strategic partnership will expand the distribution of our novel peptide-based bioink products to new and existing customers worldwide and provide Regemat3D with an extended platform to provide their customers a robust synthetic bioink for use with their very successful range of bioprinters.” 

Biogelx-INKs. Photo via Biogelx.
Biogelx-INKs. Photo via Biogelx.

Biogelx and 3D bioprinting

Biogelx spun-out from the Ulijn Group, a company focused on minimalistic molecular materials and adaptive systems at the University of Strathclyde, Glasgow. It has developed self-assembling synthetic peptide products for 3D cell culture supporting regenerative medicines and drug discovery. 

Earlier this year, Biogelx released Biogelx-INKs, its first 3D bioprinter ink to the market. As hydrogel-based inks, Biogelx-INKs are designed to be easily printable and exhibit excellent shear-thinning properties, which reduce the stress experienced by cells when subjected to the printing process. 

Last month, the company set its sights on the Brazilian medical sector following a partnership with 3D Biotechnology Solutions (3DBS), a startup specializing in custom bioprinter and electrospinning machines.

A sample of 3D printed Biogelx™-INK. Photo via Biogelx
A sample of 3D printed Biogelx-INK. Photo via Biogelx.

Regemat 3D accelerates tissue engineering

Regemat 3D was founded in 2011 by Jose Manuel Baena, Ph.D. in Biomedicine from the University of Granada, Spain and MSc Engineering from Polytechnic University of ValenciaThe company manufactures both standard and personalized inkjet bioprinters and is presently developing clinical and pre-clinical models from cartilage to living tissues in over 20 countries.

“Regemat 3D is always seeking out the best 3D bioprinting technologies solutions that the researchers need,” stated Manuel Figueruela, CEO of Regemat 3D. “We do believe that this new collaboration with Biogelx will open a new opportunity to offer something new and exciting for researchers to enjoy a true combination of consistency, reproducibility, and value for money.”

“The two brands together offer something new and exciting for researchers to enjoy a true combination of consistency, reproducibility, and value for money. We’re thrilled to be working with Biogelx on this exciting opportunity.”

Biogelx-INKs on a Regemat 3D bioprinting system. Photo via Biogelx.
Biogelx-INKs on a Regemat 3D bioprinting system. Photo via Biogelx.

Subscribe to the 3D Printing Industry newsletter, like us on Facebook and follow us on Twitter for all the latest 3D bioprinting news. Visit 3D Printing Jobs for new opportunities in additive manufacturing.

Featured image show Biogelx-INKs on a Regemat 3D bioprinting system. Photo via Biogelx.



Source link

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close